Contineum Therapeutics (CTNM) Net Income towards Common Stockholders (2023 - 2026)

Contineum Therapeutics' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$38.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 140.43% year-over-year to -$38.4 million in Q1 2026; TTM through Mar 2026 was -$91.3 million, a 83.2% decrease from a year earlier, with the FY2025 full-year figure at -$115.8 million, down 174.1% from the prior year.
• Net Income towards Common Stockholders fell to -$38.4 million in Q1 2026 per CTNM's latest filing, from -$24.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $41.6 million in Q2 2023 and bottomed at -$38.4 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$10.3 million (2024), against an average of -$9.7 million.
• Across the five-year window, Net Income towards Common Stockholders declined 24.59% in 2025 and tumbled 140.43% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$7.3 million in 2023, then plunged by 98.57% to -$14.6 million in 2024, then sank by 64.88% to -$24.0 million in 2025, then slumped by 60.09% to -$38.4 million in 2026.
• Per Business Quant, the three latest CTNM Net Income towards Common Stockholders figures stand at -$38.4 million (Q1 2026), -$24.0 million (Q4 2025), and -$12.8 million (Q3 2025).